Clinical Trials Logo

Clinical Trial Summary

The main objective is to verify that the administration of piperacillin / tazobactam administered by continuous infusion to treat complicated infections or with known or suspected nosocomial isolation of Pseudomonas aeruginosa is superior in efficacy to a 30% higher dose administered in conventional short infusion.

The secondary objectives were compared between the following variables:

- Microbiological response at 3 days of starting treatment

- Time to microbiological cure

- Clinical response at 3 days of starting treatment

- Time to achieve defervescence

- To examine the relationship between pharmacokinetic variables and parameters of efficacy and safety

- To test the hypothesis that continuous infusion maintains adequate plasma drug levels compared with levels achieved with intermittent administration.

- Cost-effectiveness analysis

- Occurrence of adverse effects

To this end, we designed a multicenter, randomized, controlled, double blind, comparing both forms of administration in patients with complicated or nosocomial infection with or without isolation of Pseudomonas aeruginosa.

Patients who are candidates for inclusion are classified according to APACHE II and to have or not isolation of Pseudomonas aeruginosa. Subsequently be randomized to receive piperacillin-tazobactam by continuous infusion or short. Primary endpoint was measured as the ultimate effectiveness of treatment and other variables such as high efficiency, safety, pharmacokinetic and pharmacoeconomic.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01577368
Study type Interventional
Source Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Contact
Status Completed
Phase Phase 3
Start date May 2011
Completion date August 2014

See also
  Status Clinical Trial Phase
Recruiting NCT06093191 - Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis Phase 4
Completed NCT02421120 - Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Phase 4
Recruiting NCT06319235 - Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Phase 1/Phase 2
Completed NCT04803708 - Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers Phase 1/Phase 2
Active, not recruiting NCT01563263 - Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Phase 2/Phase 3
Completed NCT01315678 - Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections Phase 3
Completed NCT01429259 - Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children Phase 4
Recruiting NCT06417593 - Phenotypic and Genotypic Characteristics of Pseudomonas Aeruginosa Isolates in Sohag University Hospitals
No longer available NCT04636554 - Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia